MARKET

TNYA

TNYA

Tenaya Therapeutics, Inc.
NASDAQ
4.430
+0.110
+2.55%
Closed 16:00 04/22 EDT
OPEN
4.330
PREV CLOSE
4.320
HIGH
4.514
LOW
4.260
VOLUME
296.66K
TURNOVER
0
52 WEEK HIGH
8.09
52 WEEK LOW
1.660
MARKET CAP
347.83M
P/E (TTM)
-2.6342
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TNYA last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at TNYA last week (0408-0412)?
Weekly Report · 04/15 09:22
Weekly Report: what happened at TNYA last week (0401-0405)?
Weekly Report · 04/08 09:24
Institutions along with private equity firms who hold considerable shares inTenaya Therapeutics, Inc. (NASDAQ:TNYA) come under pressure; lose 10% of holdings value
Private equity firms hold 44% of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) The top 4 shareholders of the company hold more than half of the stock. The company has a large number of institutional investors, but the majority of shares are held by private equity firms. The majority of the business is held by the top four shareholders. TenayaTherapeutics has a history of insider buying and selling, but there are 5 warning signs it may be over-valued. It's worth looking at Tenayatherapeutics's earnings history to see if insiders are buying or selling.
Simply Wall St · 04/07 13:02
Tenaya Therapeutics’ Strategic Advantages in Cardiovascular Genetic Medicine Garner Buy Rating
TipRanks · 04/05 10:56
Weekly Report: what happened at TNYA last week (0325-0329)?
Weekly Report · 04/01 09:23
Optimistic Buy Rating for Tenaya Therapeutics Based on Promising Gene Therapy Pipeline and Upcoming Clinical Milestones
TipRanks · 03/28 11:05
Weekly Report: what happened at TNYA last week (0318-0322)?
Weekly Report · 03/25 09:24
More
About TNYA
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.

Webull offers Tenaya Therapeutics Inc stock information, including NASDAQ: TNYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNYA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TNYA stock methods without spending real money on the virtual paper trading platform.